Therapy and prophylaxis of acute and late radiation-induced sequelae of the esophagus.
BACKGROUND
Radiation-induced esophagitis is a frequent acute side effect in curative and palliative radiotherapy of thoracal and cervical tumors. Late reactions are rare but might be severe.


METHODS
A research for reports on prophylactic and supportive therapies of radiation-induced esophagitis was performed (Medline, Cancerlit, and others).


RESULTS
Nutrition must be ensured and symptomatic relief of sequelae is important, especially in the case of dysphagia. The latter can be improved by topic or systemic analgetics. If esophageal spasm occurs, calcium antagonists might help. In case of gastro-esophageal reflux proton pump inhibitors should be used. There is no effective prophylactic measure for radiation esophagitis. Late side effects with clinical relevance are rare in conventional radiotherapy. Chronic ulcera, fistula or stenosis may develop. Before any treatment, a tumor infiltration of the esophagus should be excluded by biopsy. This can lead more often to late complications than radiation therapy itself. Nutrition should be ensured by endoscopic dilation, stent-implantation, or endoscopic percutaneous gastrostomy. Local injection of steroids might be used to avoid an early restenosis.


CONCLUSIONS
An intensive symptomatic therapy of acute esophagitis is reasonable. Effective prophylaxis do not exist. Late radiation induced sequelae is rare. Therefore, a tumor recurrence should be excluded in cases of dysphagia. Securing nutrition by PEG, stent, or port is well in the fore.
Zimmermann
F B
FB
Klinik und Poliklinik für Strahlentherapie und Radiologische Onkologie, Klinikum rechts der Isar, München. Frank.Zimmermann@lrz.tu-muenchen.de
Geinitz
H
H
Feldmann
H J
HJ
D004999:Amifostine / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D003680:Deglutition Disorders / Q000209:etiology / Q000517:prevention & control; D004941:Esophagitis / Q000150:complications / Q000517:prevention & control / Q000628:therapy*; D004947:Esophagus / Q000473:pathology / Q000528:radiation effects; D006801:Humans; D009092:Mucous Membrane / Q000473:pathology / Q000528:radiation effects; D011832:Radiation Injuries / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D011837:Radiation-Protective Agents / Q000627:therapeutic use; D011878:Radiotherapy / Q000009:adverse effects*; D013392:Sucralfate / Q000627:therapeutic use
D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D011837:Radiation-Protective Agents; D013392:Sucralfate; D004999:Amifostine